

July 15, 2020

Dear Valued Customer and Partner,

We would like to update to our communications regarding the impact of the COVID-19 pandemic on our activity. At the beginning of the pandemic crisis, Biokit was identified as belonging to an essential sector. Therefore, our activities during the suspension period continued in order to fulfill the reagent and biomaterials needs from our customers and partners.

To date, we have been able to meet our commitments without any disruption in the manufacturing or delivery of any product.

Even more, we have succeeded in adapting our operations and supply chain to cover the increased demand of those of our products that contribute to improve the management of COVID-19 patients in hospitals. This achievement has been possible thanks to the strong commitment of our employees with the patients. We sincerely thank them for their effort.

We continue monitoring the pandemic situation to ensure the supply of products to our customers according to their expectations, while applying the necessary measures to keep employees and partners safe.

Should you need any additional information, please contact your OEM Business Managers directly or alternatively through our e-mail address OEM@biokit.com

Sincerely,



José Luis Zarroca
CEO